Page last updated: 2024-10-21

3-aminobenzamide and Diabetes Mellitus, Type 2

3-aminobenzamide has been researched along with Diabetes Mellitus, Type 2 in 2 studies

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Choi, SK1
Galán, M1
Kassan, M1
Partyka, M1
Trebak, M1
Matrougui, K1
Szabó, C1
Biser, A1
Benko, R1
Böttinger, E1
Suszták, K1

Other Studies

2 other studies available for 3-aminobenzamide and Diabetes Mellitus, Type 2

ArticleYear
Poly(ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus.
    Hypertension (Dallas, Tex. : 1979), 2012, Volume: 59, Issue:5

    Topics: Animals; Benzimidazoles; Blood Glucose; Blood Pressure Determination; Blotting, Western; Body Weight

2012
Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice.
    Diabetes, 2006, Volume: 55, Issue:11

    Topics: Animals; Apoptosis; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies;

2006